Home › Articles › Volume 7, Issue 4 › A Study on the Efficacy of 24 Weeks of Sofosbuvir, D...
Moradabad, India
Original Article
Medicine

A Study on the Efficacy of 24 Weeks of Sofosbuvir, Daclatasvir with Ribaravin in the Treatment of Chronic Hepatitis C Patients with Cirrhosis, Genotype 1 and 3.


Volume 7, Issue 4, Pages 25-28

Authors

Nitali Arun1, Anand Dev2, V.K.Singh3
Affiliation:
1Assistant Professor, Department of Microbiology, TMMC & RC,
2Assistant Professor, Department of Internal Medicine, TMMC & RC, Moradabad
3Professor and Head, Department of Internal Medicine, TMMC & RC, Moradabad.

Corresponding Author

Anand Dev

Abstract

Background: A number of new interferon free regimens involving direct-acting antiviral agents have recently been approved in EASL 2016 guidelines for the treatment of chronic hepatitis c, cirrhotic patients with genotype1 and 3. Our aim was to assess the efficacy of one such combination of Sofosbuvir, Daclatasvir with Ribaravin after a period of 24 weeks of treatment. Subjects and Methods: 200 patients with hepatitis C and cirrhosis infected with genotype 3 and 1 were included in our study. They were treated with Sofosbuvir 400mg, Daclatasvir 60 mg and weight based Ribavirin for 24 weeks. Response to treatment was assessed 12 weeks after the end of treatment with a sensitive assay (SVR12). Results: Sustained virological response after 12 weeks of end of treatment (SVR12) was achieved in 97.8% of the patients. Among the 4 patients who did not achieve SVR, all were infected with genotype 3 suggesting comparatively greater difficulty in treating this genotype with the available DAA’s. Treatment had to be discontinued in 3 patients due to rise in serum creatinine following acute gastroenteritis. 2 patients died due to sepsis. The most common treatment related adverse events were fatigue, headache, cough and sleep related disturbances. No treatment related adverse events related in discontinuation of treatment. Conclusion: Combination of Sofosbuvir and Daclatasvir with weight based Ribavirin for 24 weeks is highly effective and safe in treating cirrhotic HCV patients with Genotypes 3 and 1.

Keywords

Sofosbuvir, Daclatasvir, Ribavarin, Hepatitis C.

History

Received 01 November 2018

Accepted 01 December 2018

DOI

10.21276/ajmr.2018.7.4.ME6

Author Notes

Corresponding Author: Dr. Anand Dev, Assistant Professor, Department of Internal Medicine, TMMC & RC, Moradabad.

Open Access

It is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. https://creativecommons.org/licenses/by-nc/4.0/

Copyright

Copyright (c) 2018 Asian Journal of Medical Research

Cite this Article

Formats

                                                
Actions
Download PDF
Metrics
7
Downloads
6
Views
Journal
Journal Asian Journal of Medical Research
Volume Volume 7
Issue Issue 4
Year 2019

Purchase access plans

Select the plan that best fits your need

Loading plans...

Statistics:

Views: 0
Downloads: 0

Asian Journal of Medical Research (AJMR) is an international, peer-reviewed, quarterly open-access journal publishing advanced research across medical specialties.

Quick Links

For Authors

© 2026 Asian Journal of Medical Research. All Rights Reserved.Designed and Developed By Kryoni